PDCD1 and non-small cell lung carcinoma: Since SMI had been reported to increase activity of NK cells combined with chemotherapy [79], combination of PD-1 inhibitor and SMI may generate synergistic therapeutic effect to recruit and activate NK cell in NSCLC.